Leading the pharmaceutical industry in the Haikou industrial economy, the output value rose 31.6% in the first half of the year

The pharmaceutical manufacturing industry is currently an advantageous industry in Haikou City, Hainan Province. After the development in recent years, the Haikou pharmaceutical manufacturing industry has achieved rapid growth. In the first half of this year, the accumulated output value was 2.142 billion yuan, an increase of 31.6% year-on-year, and the growth rate was the leading industrial economy in Haikou. Become a force in the city's industrial growth and economic development.

According to the Haikou Municipal Bureau of Industry, Industry and Commerce, in recent years, Haikou pharmaceutical companies have stepped up research and development of new drugs, while increasing technological transformation efforts, expanding production capacity, improving technology and improving product quality. With the successive production of new production lines, the production capacity of Kellett, Hailing, Haipang, and Haishen Tongzhou quickly increased. Each drug company seizes market opportunities and continuously expands the market, and its output value maintains a trend of rapid growth. In the first half of this year, Kellett Pharmaceuticals, Hexense Pharmaceuticals, Qilu Pharmaceuticals, Lingkang Pharmaceuticals, and Asia Pharmaceuticals all achieved growth of more than 30%, of which Kellett Pharmaceuticals and Hexense Pharmaceuticals had an increase of more than 100%.

“This large growth is related to the increase of independent innovation and technological transformation by enterprises, and the continuous expansion of the market by enterprises. As companies continue to develop new products and occupy the commanding heights of the market, the market demand also continues to grow.” Haikou City Science and Technology Letter Bureau official said.

Since the beginning of this year, Haishen Tongzhou Pharmaceutical Co., Ltd. has increased its R&D investment, and has successfully declared a number of patents such as gastrointestinal granules and their preparation methods, soft capsules for detoxification and detoxification, and their preparation methods, and has obtained the national patent right for inventions. The relevant person in charge of the company said: "Through R&D and independent innovation, we have reserved a batch of state-level innovative drugs that have independent intellectual property rights and have reached the international advanced level so that we can seize market initiative and improve the market competitiveness of our products." In half a year, the company achieved sales revenue of 50.87 million yuan, an increase of more than 30% year-on-year.

While enterprises increased R&D and independent innovation, a group of companies are accelerating their expansion and expansion of their production scale. Qilu Phase I, Kangzhi Pharmaceutical Phase I and Aike Pharmaceutical have completed production and commissioning; CITIC Pharmaceutical and other companies are installing equipment; Haishen Tongzhou, Huangjiang Pharmaceutical, Sinochem United Pharmaceuticals and other projects are accelerating their construction; Hailing Pharmaceutical Phase II, Asia Pharmaceuticals and other projects are carrying out pre-project work. After these projects are completed, they will further enhance the development potential of the Haikou pharmaceutical industry and promote the rapid development of the industrial economy.

In addition, Haikou pharmaceutical companies also actively promote the listing, there are currently five pharmaceutical companies such as Haipang, Star Pharmaceuticals, Xiansheng Pharmaceutical and Kangzhi Pharmaceutical successfully listed.